xenon-129

Trade name: Xenoview

Small moleculeapprovedImaging agent

Approved

Dec 23, 2022

Naturally occurring xenon (54Xe) consists of seven stable isotopes and two very long-lived isotopes. Double electron capture has been observed in 124Xe and double beta decay in 136Xe, which are among the longest measured half-lives of all nuclides. The isotopes 126Xe and 134Xe are also predicted to undergo double beta decay, but this process has never been observed in these isotopes, so they are considered to be stable. Beyond these stable forms, 32 artificial unstable isotopes and various isomers have been studied, the longest-lived of which is 127Xe with a half-life of 36.342 days. All other nuclides have half-lives less than 12 days, most less than 20 hours. The shortest-lived isotope, 108Xe, has a half-life of 58 μs, and is the heaviest known nuclide with equal numbers of protons and neutrons. Of known isomers, the longest-lived is 131mXe with a half-life of 11.948 days. — Wikipedia

Clinical trial activity

65 trials · 44 clinical orgs · 1 marketing orgs

Phase 1
26
Phase 2
31
Phase 3
7
Phase 4
5

Earliest trial started Sep 30, 1997 (NCT03764163)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Polarean Inc. — Earliest Phase 3 Sponsor(trial)

2020s

  1. Dec 23, 2022

    Polarean Inc. — Earliest FDA Approval

  2. Dec 23, 2022

    Polarean Inc. — Marketing Organization

  3. Dec 23, 2022

    Polarean Inc. — NDA Secondary Org

  4. Dec 23, 2022

    Polarean Inc. — NDA Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedDec 23, 2022

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 129-xenon
  • ge-141, hyperpolarized 129xenon gas
  • hyperpolarized xenon
  • xenon-129
  • xenon-129

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06909201Early Phase 1 (Phase 1)Oct 16, 2025University of Texas at Houston
NCT06925295Phase 2Aug 31, 2025University of Iowa
NCT06945614Phase 1Apr 16, 2025General Biophysics LLC, National Institute on Aging (NIA)
NCT06853145Early Phase 1 (Phase 1)Mar 31, 2025University of Virginia
NCT06856525Phase 2/Phase 3 (Phase 3)Dec 6, 2024Duke University, George Mason University, University of Virginia
NCT06351345Phase 2Sep 1, 2024Duke University, Merck
NCT06122922Phase 2Mar 15, 2024Duke University, Regeneron
NCT06038630Phase 2Jan 31, 2024Duke University, National Institutes of Health (NIH)
NCT06104228Phase 2Jan 1, 2024American Heart Association, Duke University
NCT06080100Early Phase 1 (Phase 1)Nov 1, 2023GMP BIO Co., LTD., The S.N. Fyodorov Eye Microsurgery State Institution
NCT05838703Phase 2May 1, 2023Duke University
NCT05550662Phase 2Jan 15, 2023University of Toronto
NCT05335109Phase 3Dec 1, 2022Negovsky Reanimatology Research Institute
NCT05433961Phase 1Aug 1, 2022University of Pennsylvania, Xemed LLC
NCT05241275Phase 2Jul 19, 2022Boehringer Ingelheim, Duke University
NCT05517655Phase 4May 1, 2022University of Cincinnati, University of Iowa, University of Kansas, University of Virginia
NCT05302817Phase 1Mar 17, 2022University of Pennsylvania, Xemed LLC
NCT04677426Phase 2Jan 1, 2022Boehringer Ingelheim, Duke University, University of Cincinnati, University of Kansas
NCT04778046Phase 2Dec 1, 2021Duke University
NCT04855305Phase 2Nov 12, 2021Duke University, National Heart, Lung, and Blood Institute (NHLBI), University of Cincinnati, University of Iowa
Showing 20 of 65 trials
Page 1 / 4

Organizations

Research & Development (44)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Duke UniversityAcademic/Hospital201732015
University of CincinnatiAcademic/Hospital9722014
National Heart, Lung, and Blood Institute (NHLBI)Government7021997
University of VirginiaAcademic/Hospital7642016
University of Western OntarioAcademic/Hospital6322011
National Institutes of Health (NIH)Government5031997
University of IowaAcademic/Hospital4231997
University of KansasAcademic/Hospital4332020
University of PennsylvaniaAcademic/Hospital4012019
Xemed LLCFor profit4412019
Nobilis Therapeutics Inc.For profit3322018
Boehringer IngelheimFor profit2012022
Harvard UniversityAcademic/Hospital2222013
Lakehead UniversityAcademic/Hospital2012016
Northern Ontario School of MedicineAcademic/Hospital2212016
Polarean Inc.For profit2212018
University of TorontoAcademic/Hospital2212015
American Heart AssociationAcademic/Hospital1012024
AstraZenecaFor profit1012019
Cystic Fibrosis Foundation TherapeuticsAcademic/Hospital1012018
44 organizations
Page 1 / 3

Marketing (3)

OrganizationOrg typeRelationshipDate
Polarean Inc.For profitMKTGDec 23, 2022
Polarean Inc.For profitNDA2Dec 23, 2022
Polarean Inc.For profitNDADec 23, 2022